NCT05853458 2026-04-22
HU-F-AIM
Novartis
Phase 4 Terminated
Clinical Trials
16 trialsNCT07190833 2026-04-09
A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)
Bionoxx Inc.
Phase 1 Recruiting
NCT07170592 2026-04-07
A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients
Bionoxx Inc.
Phase 1 Not yet recruiting
NCT06093672 2026-03-25
GIV-IN-PV
Italfarmaco
Phase 3 Recruiting
NCT06063317 2026-03-06
OASIS
Imugene Limited
Phase 1 Terminated
NCT07033598 2026-03-05
PROSPERA
Theradex
Phase 2 Recruiting
NCT05020652 2025-12-17
A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Active not recruiting
NCT03860844 2025-09-09
ISAKIDS
Sanofi
Phase 2 Terminated
NCT04126681 2025-03-03
A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase
Ascentage Pharma Group Inc.
Phase 2 Completed
NCT02088541 2023-01-26
SOPRA
Karyopharm Therapeutics Inc
Phase 2 Completed
NCT00928707 2019-10-31
PV
Italfarmaco
Phase 2 Completed
NCT01243944 2019-03-06
Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)
Incyte Corporation
Phase 3 Completed
NCT01632904 2017-11-14
Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
Incyte Corporation
Phase 3 Completed
NCT01949805 2016-11-28
PROUD-PV
AOP Orphan Pharmaceuticals AG
Phase 3 Completed
NCT00290771 2011-05-16
Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)
Novartis
Phase 2 Terminated
NCT00154375 2011-04-26
Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma
Novartis
Phase 3 Completed